NIH funded new influenza research network
On Apr. 15, 2021, the National Institute of Allergy and Infectious Diseases (NIAID) announced it had had established…
NIAID trial of Anti-CD14 antibody to treat COVID-19 respiratory disease began
On Apr. 13, 2021, a clinical trial testing the safety and efficacy of an investigational monoclonal antibody for…
Phase III trial showed subcutaneous administration of investigational antibody cocktail reduced risk of symptomatic COVID-19 infections by 81%
On Apr. 12, 2021, Roche confirmed positive results from the phase III REGN-COV 2069 trial assessing the ability…
NIH clinical trial evaluating Moderna COVID-19 variant vaccine began
On Mar. 31, 2021, the NIH announced that an investigational vaccine designed to protect against the B.1.351 SARS-CoV-2…
Measles vaccine used as base for experimental COVID vaccine
On Apr. 1, 2021, Kaiser Permanente Washington Health Research Institute (KPWHRI) announced that an investigational vaccine designed to…
T cells recognize recent SARS-CoV-2 variants
On Mar. 30, 2021, the National Institute of Allergy and Infectious Diseases (NIAID) announced that researchers had analyzed…
Monoclonal antibodies against MERS Coronavirus showed promise in phase 1 NIH-sponsored trial
On Feb. 23, 2021, the NIH announced that a randomized, placebo-controlled Phase 1 clinical trial of two monoclonal…
Clinical trial in hospitalized COVID-19 patients evaluate long-acting antibody therapy
On Feb. 8, 2021, the NIH announced that an international randomized, controlled Phase 3 clinical trial had begun…
Antibody infusions prevented acquisition of some HIV strains, NIH studies found
On Jan. 26, 2021, NIH researchers announced that an investigational anti-HIV antibody delivered intravenously once every eight weeks…
Regeneron reported positive data with REGEN-COV antibody cocktail as passive vaccine to prevent COVID-19
On Jan. 26, 2021, Regeneron announced positive initial results from an ongoing Phase 3 clinical trial evaluating REGEN-COV…
A closer look at T cells revealed big differences in mild vs severe COVID-19 cases
On Jan. 21, 2021, NIH researchers announced that after people recover from infection with a virus, the immune…
European Commission approved Aimmune’s PALFORZIA as first-ever treatment for peanut allergy in the EU
On Dec. 21, 2020, Aimmune Therapeutics announced that the European Commission (EC) had approved PALFORZIA [defatted powder of…
NIH observational study of coronavirus infection and multisystem inflammatory syndrome in children began
On Dec. 16, 2020, National Institute of Allergy and Infectious Diseases reported that an observational study had launched…
Peanut allergy treatment significantly lowered risk of life-threatening reactions in preschoolers
On Dec. 3, 2020, a new study by researchers at the University of British Columbia and BC Children’s…
Experimental vaccine for deadly tickborne virus effective in cynomolgus macaques
On Nov. 25, 2020, the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes…
Moderna completed enrollment of phase 3 COVE study of mRNA vaccine against COVID-19
On Oct. 22, 2020, Moderna announced that it had completed enrollment of 30,000 participants for the Phase 3…
NIAID clinical trial testing hyperimmune intravenous immunoglobulin plus remdesivir to treat COVID-19 began
On Oct. 8, 2020, a clinical trial to test the safety, tolerability and efficacy of a combination treatment…
NIH clinical trial testing hyperimmune intravenous immunoglobulin plus remdesivir to treat COVID-19 began
On Oct. 8, 2020, a clinical trial to test the safety, tolerability and efficacy of a combination treatment…
Investigational COVID-19 vaccine well tolerated and generated iImmune response in older adults
On Sept. 29, 2020, the National Institute of Allergy and Infectious Diseases announced that a phase 1 trial…
COVID-19 vaccine generated immune response in older adults
On Sept. 29, 2020, a phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection was…
Baricitinib in combination with remdesivir reduced time to recovery in hospitalized patients with COVID-19 in ACTT-2 Trial
On Sept. 14, 2020, Eli Lilly and Incyte announced initial data from the Adaptive COVID-19 Treatment Trial (ACTT-2)…
HDT BIO received NIH contract to advance novel RNA/LIONï¾™ COVID-19 vaccine into clinical trials
On Sept. 1, 2020, HDT Bio received a notice of award from the National Institute of Allergy and…
NIAID awarded BioCryst $44 million contract to advance development of galidesivir
On Aug. 31, 2020, BioCryst Pharmaceuticals announced that the National Institute of Allergy and Infectious Diseases (NIAID) had…
Biotechnology | COVID-19 | Disease | Medicine | NIH | Therapeutics
La Jolla Institute for Immunology awarded $6.4 million for international efforts to beat COVID-19
On Aug. 20, 2020, the La Jolla Institute for Immunology (LJI) announced that Erica Ollmann Saphire, Ph.D. had…
Intravacc received US NIH/NIAID contract to develop Enterovirus D68 Vaccine
On Aug. 9, 2020, Intravacc announced that it had been awarded a contract with base and options that…
Phase 3 clinical trial of investigational vaccine for COVID-19 began
On Jul. 27, 2020, a phase 3 clinical trial designed to evaluate if an investigational vaccine can prevent…
COVID-19 | Life Science News | NIH | Vaccine
Experimental coronavirus vaccine reported safe and produces immune response
On Jul. 21, 2020, researchers announced that early results from the first COVID-19 vaccine candidate tested in people…
Dynavax and Mount Sinai announced collaboration to develop a universal influenza vaccine candidate with CpG 1018 adjuvant
On Jul. 16, 2020, Dynavax Technologies and the Icahn School of Medicine at Mount Sinai announced they had…
Experimental Coronavirus vaccine is safe and produced immune response
On Jul. 14, 2020, NIH researchers reported early results from the first COVID-19 vaccine candidate tested in people…
NIH launched clinical trials network to test COVID-19 vaccines and other prevention tools
On Jul. 8, 2020, the National Institute of Allergy and Infectious Diseases announced it had established a new…